| Merck KGaA: New Data Reinforce Consistent Efficacy Profile of Erbitux in First-Line mCRC Patients with KRAS Wild-Type Tumors
|
(Merck KGaA)
|
14-Jan-2009 |
| Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
|
(Anthera Pharmaceuticals)
|
12-Jan-2009 |
| Anthera Announces Completion of Enrollment and Dosing in Francis Trial of A-002 for the Treatment of Cardiovascular Disease
|
(Anthera Pharmaceuticals)
|
12-Jan-2009 |
| Trials Show Next-Generation GRII Receptor Antagonist Prevents and Reverses Weight Gain Associated With Use of Olanzapine -- the Active Ingredient in Zyprexa(R)
|
(Corcept Therapeutics)
|
08-Jan-2009 |
| FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults
|
(Eli Lilly)
|
07-Jan-2009 |
| Notable regulatory events over the Christmas period
|
(Takeda)
|
05-Jan-2009 |
| FDA Cardio Renal Advisory Committee to Review Daiichi Sankyo, Lilly Drug Prasugrel
|
(Eli Lilly)
|
31-Dec-2008 |
| FDA Cardio Renal Advisory Committee to Review Daiichi Sankyo, Lilly Drug Prasugrel
|
(Daiichi Sankyo)
|
31-Dec-2008 |
| Biomarker moves into the spotlight as FDA goes wild for KRAS
|
(ImClone Systems)
|
19-Dec-2008 |
| Prasugrel Receives Positive Opinion from the European Committee for Medicinal Products for Human Use (CHMP)
|
(Daiichi Sankyo)
|
18-Dec-2008 |
| Prasugrel Receives Positive Opinion from the European Committee for Medicinal Products for Human Use (CHMP)
|
(Eli Lilly)
|
18-Dec-2008 |
| Akorn, Inc. Responds to FDA Draft Guidance for Industry on Bioequivalence Recommendation for Vancomycin HCl
|
(Akorn)
|
16-Dec-2008 |
| Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback
|
(Eli Lilly)
|
11-Dec-2008 |
| Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback
|
(Alkermes)
|
11-Dec-2008 |
| Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback
|
(Amylin Pharmaceuticals)
|
11-Dec-2008 |
| Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance
|
(Eli Lilly)
|
11-Dec-2008 |
| Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R)
|
(Eli Lilly)
|
10-Dec-2008 |
| Study Showed New Episodes of Depression Delayed in People Taking Duloxetine
|
(Boehringer Ingelheim)
|
10-Dec-2008 |
| ERBITUX® Supplemental Biologics License Application for Advanced Non-Small Cell Lung Cancer Submitted To U.S. Food and Drug Administration
|
(Eli Lilly)
|
08-Dec-2008 |
| ERBITUX® Supplemental Biologics License Application for Advanced Non-Small Cell Lung Cancer Submitted to U.S. Food and Drug Administration
|
(Bristol-Myers Squibb)
|
08-Dec-2008 |
| Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
|
(Eli Lilly)
|
08-Dec-2008 |
| Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
|
(Amylin Pharmaceuticals)
|
08-Dec-2008 |
| FDA Issues Complete Response Letter for Oritavancin
|
(Targanta Therapeutics)
|
08-Dec-2008 |
| Merck KGaA: European Commission Approves Erbitux for First-Line Use in Head and Neck Cancer
|
(Merck KGaA)
|
01-Dec-2008 |
| MedImmune Receives FDA Complete Response Letter on Motavizumab
|
(AstraZeneca)
|
28-Nov-2008 |
| Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
|
(Eli Lilly)
|
28-Nov-2008 |
| ImClone Systems' State-of-the-Art Manufacturing Facility Receives FDA Approval for Multi-Product Biologics Production
|
(ImClone Systems)
|
20-Nov-2008 |
| Randomized Phase 2 Study of IMC-A12 for HER2-Expressing Advanced Breast Cancer Commences Patient Enrollment
|
(ImClone Systems)
|
19-Nov-2008 |
| FDA Advisory Committee Provides Opinion on Oritavancin for the Treatment of Complicated Skin and Skin Structure Infections
|
(Targanta Therapeutics)
|
19-Nov-2008 |
| Study Published in Archives of Surgery Demonstrated Benefit of ENTEREG(R) (alvimopan) in Postoperative Ileus
|
(Adolor)
|
18-Nov-2008 |
| Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem(R) Pulvules(R) Capsules
|
(Mylan)
|
18-Nov-2008 |
| United's clever use of substitute could give it breathing space
|
(United Therapeutics)
|
18-Nov-2008 |
| Targanta Announces Posting of Briefing Documents for Review of FDA Anti-infective Drugs Advisory Committee Meeting for Oritavancin
|
(Targanta Therapeutics)
|
17-Nov-2008 |
| Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months With Erbitux
|
(Merck KGaA)
|
13-Nov-2008 |
| Anthera’s Varespladib Demonstrates Significant Anti-inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
|
(Anthera Pharmaceuticals)
|
11-Nov-2008 |
| Phase 2 Study of IMC-1121B in First-Line Treatment of Advanced Non-Small Cell Lung Cancer Commences Patient Enrollment
|
(ImClone Systems)
|
11-Nov-2008 |
| Amylin facing crisis of confidence
|
(Amylin Pharmaceuticals)
|
05-Nov-2008 |
| New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection
|
(Vertex Pharmaceuticals)
|
01-Nov-2008 |
| ERBITUX® Supplemental Biologics License Application for First-Line Recurrent or Metastatic Head and Neck Cancer Accepted for Priority Review by U.S. Food and Drug Administration
|
(Bristol-Myers Squibb)
|
30-Oct-2008 |
| ERBITUX® Supplemental Biologics License Application for First-Line Recurrent or Metastatic Head and Neck Cancer Accepted for Priority Review by U.S. Food and Drug Administration
|
(ImClone Systems)
|
30-Oct-2008 |
| ImClone Announces ERBITUX(R) Commercial Launch in Canada for Advanced Colorectal Cancer
|
(ImClone Systems)
|
29-Oct-2008 |
| Targanta Presents Efficacy and Safety Data for Oritavancin for the Treatment of Gram-Positive Complicated Skin and Skin Structure Infections (cSSSI)
|
(Targanta Therapeutics)
|
26-Oct-2008 |
| Targanta Therapeutics Presents in Vitro Data Highlighting Oritavancin’s Potent Activity Against Gram-Positive Pathogens
|
(Targanta Therapeutics)
|
25-Oct-2008 |
| European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia
|
(Boehringer Ingelheim)
|
24-Oct-2008 |
| Merck KGaA: Erbitux Receives CHMP Positive Opinion for First-Line Use in Head and Neck Cancer
|
(Merck KGaA)
|
24-Oct-2008 |
| European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia
|
(Eli Lilly)
|
24-Oct-2008 |
| Study Published in New England Journal of Medicine Shows K-ras Gene Mutation Status May Affect Response to ERBITUX® Treatment
|
(Bristol-Myers Squibb)
|
22-Oct-2008 |
| Targanta Therapeutics Releases Results from Phase 2 SIMPLIFI Study Evaluating Single Or Infrequent Doses of Oritavancin
|
(Targanta Therapeutics)
|
22-Oct-2008 |
| Study Published in New England Journal of Medicine Shows K-ras Gene Mutation Status May Affect Response to ERBITUX(R) Treatment
|
(ImClone Systems)
|
22-Oct-2008 |
| Daiichi and Lilly come out fighting for prasugrel
|
(Eli Lilly)
|
17-Oct-2008 |
| Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
|
(Eli Lilly)
|
16-Oct-2008 |
| FDA Grants Full Approval to ONTAK® (denileukin diftitox) For Use in Patients with Cutaneous T-Cell Lymphoma (CTCL)
|
(Eisai)
|
16-Oct-2008 |
| Daiichi Sankyo and Lilly Respond to Speculation On Status of Prasugrel New Drug Application
|
(Daiichi Sankyo)
|
16-Oct-2008 |
| Wockhardt Gets US FDA Nod to Market Ceftazidime Injections
|
(Wockhardt)
|
16-Oct-2008 |
| Biothera Initiates Second Arm of Metastatic Colorectal Cancer Trial
|
(Biothera)
|
15-Oct-2008 |
| Tibotec Begins Enrollment for Phase III Study of Telaprevir, an Investigational Agent, in HCV Patients Who Failed Prior Treatment
|
(Johnson & Johnson)
|
15-Oct-2008 |
| Lilly Launches New FORTEO Delivery Device
|
(Eli Lilly)
|
15-Oct-2008 |
| Targanta Announces Review of Oritavancin at FDA Anti-Infective Drugs Advisory Committee Meeting
|
(Targanta Therapeutics)
|
14-Oct-2008 |
| Biothera Completes Enrollment of First Arm of Metastatic Colorectal Cancer Trial
|
(Biothera)
|
07-Oct-2008 |
| BioMS Medical’s Relapsing-remitting Multiple Sclerosis Trial Receives Positive Review from Data Safety Monitoring Board
|
(BioMS Medical)
|
06-Oct-2008 |
| BioMS Medical's Phase III U.S. Multiple Sclerosis Trial Receives Positive Safety Review from Data Safety Monitoring Board
|
(BioMS Medical)
|
03-Oct-2008 |
| Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimer's Disease Compound
|
(Eli Lilly)
|
01-Oct-2008 |
| Phase 2 Study of IMC-1121B for Advanced Ovarian Cancer Commences Patient Enrollment
|
(ImClone Systems)
|
30-Sep-2008 |
| Further Effient delays hurt Lilly and Daiichi
|
(Eli Lilly)
|
29-Sep-2008 |
| FDA Grants Lilly's ALIMTA(R) (Pemetrexed for Injection) Third U.S. Approval
|
(Eli Lilly)
|
29-Sep-2008 |
| CHMP Recommends Approval of Olanzapine Long-acting Injection for Maintenance Treatment of Schizophrenia in Europe
|
(Eli Lilly)
|
26-Sep-2008 |
| Zypadhera(TM) Receives Positive Opinion from the European Committee for Medicinal Products for Human Use (CHMP) for Maintenance Treatment of Schizophrenia
|
(Eli Lilly)
|
26-Sep-2008 |
| FDA Continues to Review Prasugrel New Drug Application
|
(Daiichi Sankyo)
|
26-Sep-2008 |
| FDA Continues to Review Prasugrel New Drug Application
|
(Eli Lilly)
|
26-Sep-2008 |
| Randomized Phase 2 Study of IMC-A12 for Advanced Breast Cancer Commences Patient Enrollment
|
(ImClone Systems)
|
25-Sep-2008 |
| Telaprevir Presentations at the 59th AASLD Meeting to Feature SVR Data in Treatment-NaAve and Treatment-Failure Genotype 1 HCV Patients, and Clinical Data Exploring Twice-Daily Dosing Regimens
|
(Vertex Pharmaceuticals)
|
24-Sep-2008 |
| Anthera Completes Special Protocol Assessment with FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
|
(Anthera Pharmaceuticals)
|
24-Sep-2008 |
| ERBITUX(R) Five-Year Data Show Significant Improvement in Overall Survival for Patients with Locally or Regionally Advanced Head and Neck Cancer
|
(Bristol-Myers Squibb)
|
22-Sep-2008 |
| BioMS Medical Announces Receipt of Milestone Payment from Eli Lilly and Company
|
(BioMS Medical)
|
22-Sep-2008 |
| ERBITUX(R) Five-Year Data Show Significant Improvement in Overall Survival for Patients with Locally or Regionally Advanced Head and Neck Cancer
|
(ImClone Systems)
|
22-Sep-2008 |
| ERBITUX(R) Now Available in Japan for Use in Treating Patients with Advanced Colorectal Cancer
|
(ImClone Systems)
|
19-Sep-2008 |
| ImClone Provides Update on Pivotal Phase 3 CRYSTAL Study in First-Line Metastatic Colorectal Cancer
|
(ImClone Systems)
|
16-Sep-2008 |
| Merck KGaA: Erbitux Extends Survival from 21 to 25 Months for Patients with Metastatic Colorectal Cancer and KRAS Wild-Type Tumors
|
(Merck KGaA)
|
16-Sep-2008 |
| Merck KGaA: New First-Line Data Demonstrate Response Rates of Up 80% for Erbitux in KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)
|
(Merck KGaA)
|
16-Sep-2008 |
| Wrangles over Erbitux follow-on central to ImClone takeover
|
(Bristol-Myers Squibb)
|
12-Sep-2008 |
| Transition Therapeutics Dose First Patient in Phase 2 Clinical Study of TT-223 in Type 2 Diabetes
|
(Transition Therapeutics)
|
12-Sep-2008 |
| Merck KGaA Submits New License Application for Erbitux in Firstline Non-Small Cell Lung Cancer in Europe
|
(Merck KGaA)
|
11-Sep-2008 |
| Study Published in New England Journal of Medicine Shows ERBITUX(R) Improved Survival in First-Line Recurrent And/Or Metastatic Head and Neck Cancer
|
(ImClone Systems)
|
10-Sep-2008 |
| Study Published in New England Journal of Medicine Shows ERBITUX® Improved Survival in First-Line Recurrent And/Or Metastatic Head and Neck Cancer
|
(Bristol-Myers Squibb)
|
10-Sep-2008 |
| First Reported Head-to-Head Study Showed BYETTA® (exenatide) Injection Provided Greater Reduction in Post-Meal Glucose Levels than Januvia™ (sitagliptin) in Patients With Type 2 Diabetes
|
(Eli Lilly)
|
09-Sep-2008 |
| BioMS Medical’s Lead Drug, Dirucotide (MBP8298) for the Treatment of Multiple Sclerosis, Receives Fast Track Designation from FDA
|
(BioMS Medical)
|
04-Sep-2008 |
| New Crossover Study Shows Prasugrel Significantly Reduced Platelet Aggregation in Patients with Acute Coronary Syndromes Compared with Clopidogrel at High Doses
|
(Eli Lilly)
|
03-Sep-2008 |
| Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
|
(Eli Lilly)
|
03-Sep-2008 |
| ImClone Submits Supplemental Biologics License Application for ERBITUX(R) in First-Line Head and Neck Cancer
|
(ImClone Systems)
|
03-Sep-2008 |
| Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
|
(Daiichi Sankyo)
|
03-Sep-2008 |
| New Crossover Study Shows Prasugrel Significantly Reduced Platelet Aggregation in Patients with Acute Coronary Syndromes Compared with Clopidogrel at High Doses
|
(Daiichi Sankyo)
|
03-Sep-2008 |
| Targanta Therapeutics Announces Positive Top-Line Results from Oritavancin Phase 2 SIMPLIFI Trial
|
(Targanta Therapeutics)
|
02-Sep-2008 |
| Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months
|
(Eli Lilly)
|
02-Sep-2008 |
| Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel
|
(Eli Lilly)
|
31-Aug-2008 |
| ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
|
(ImClone Systems)
|
29-Aug-2008 |
| Alkermes feels Amylin's Byetta pain
|
(Alkermes)
|
28-Aug-2008 |
| Randomized Phase 2 Study of IMC-A12 and IMC-1121B for Advanced Prostate Cancer Commences Patient Enrollment
|
(ImClone Systems)
|
26-Aug-2008 |
| Patients Taking Cymbalta® Experienced Reduced Chronic Low Back Pain in New Study
|
(Eli Lilly)
|
25-Aug-2008 |
| Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of Francis Trial
|
(Anthera Pharmaceuticals)
|
25-Aug-2008 |
| Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder
|
(Eli Lilly)
|
22-Aug-2008 |
| Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
|
(Eli Lilly)
|
21-Aug-2008 |
| New Data Show Duloxetine Maintained Pain Reduction for More Than Six Months in Patients With Diabetic Peripheral Neuropathic Pain
|
(Boehringer Ingelheim)
|
19-Aug-2008 |
| Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
|
(Daiichi Sankyo)
|
14-Aug-2008 |
| Global Phase 3 Study of IMC-1121B in Metastatic Breast Cancer Commences
|
(ImClone Systems)
|
13-Aug-2008 |
| BioMS Medical Announces Positive Interim Analysis on Phase III Trial of Dirucotide (MBP8298) for Multiple Sclerosis
|
(BioMS Medical)
|
13-Aug-2008 |
| Phase II Data on Lilly's Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimer's Disease
|
(Eli Lilly)
|
30-Jul-2008 |
| Merck Receives European Approval for Broader Use of Erbitux in Metastatic Colorectal Cancer Including First-Line Treatment
|
(Merck KGaA)
|
23-Jul-2008 |
| Bioms Medical’s Relapsing-remitting Multiple Sclerosis Trial Receives Positive Review from Data Safety Monitoring Board
|
(BioMS Medical)
|
17-Jul-2008 |
| Merck: Erbitux Approved for Use in Metastatic Colorectal Cancer in Japan
|
(Merck KGaA)
|
16-Jul-2008 |
| ERBITUX(R) (Cetuximab) Receives Approval in Japan for Use in Advanced Colorectal Cancer
|
(ImClone Systems)
|
16-Jul-2008 |
| Merck Begins Erbitux Phase III Clinical Study in Gastric Cancer
|
(Merck KGaA)
|
09-Jul-2008 |
| Phase 2 Study Of IMC-A12 for Advanced Soft Tissue Sarcoma Opens for Patient Enrollment
|
(ImClone Systems)
|
07-Jul-2008 |
| Adolor Provides Update on Entereg(R) (alvimopan) OBD Program
|
(Adolor)
|
03-Jul-2008 |
| SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393
|
(SGX Pharmaceuticals)
|
30-Jun-2008 |
| European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
|
(Eli Lilly)
|
27-Jun-2008 |
| Targanta’s Oritavancin MAA Accepted for Review by EMEA
|
(Targanta Therapeutics)
|
25-Jun-2008 |
| IMC-A12 Plus Temsirolimus Clinical Trial for Advanced Cancer Opens for Patient Enrollment
|
(ImClone Systems)
|
25-Jun-2008 |
| Effient delay points to increasing trend for regulatory setbacks
|
(Eli Lilly)
|
24-Jun-2008 |
| Event - Lilly desperate for positive FDA verdict on Effient
|
(Eli Lilly)
|
23-Jun-2008 |
| Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
|
(Eli Lilly)
|
23-Jun-2008 |
| FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
|
(Daiichi Sankyo)
|
23-Jun-2008 |
| FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
|
(Eli Lilly)
|
23-Jun-2008 |
| Merck Applies to Extend Use of Erbitux for First-Line Head and Neck Cancer in Europe
|
(Merck KGaA)
|
19-Jun-2008 |
| Cymbalta good cheer spreads to Cypress
|
(Cypress Bioscience)
|
17-Jun-2008 |
| FDA Approves Cymbalta® for the Management of Fibromyalgia
|
(Eli Lilly)
|
16-Jun-2008 |
| Patients Taking Cymbalta® Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
|
(Eli Lilly)
|
13-Jun-2008 |
| ADA kicks off GLP-1 succession saga
|
(Amylin Pharmaceuticals)
|
10-Jun-2008 |
| After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight
|
(Amylin Pharmaceuticals)
|
09-Jun-2008 |
| After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight
|
(Eli Lilly)
|
09-Jun-2008 |
| Entereg(R) (alvimopan) Available for the Management of Postoperative Ileus
|
(Adolor)
|
09-Jun-2008 |
| After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight
|
(Alkermes)
|
09-Jun-2008 |
| Targanta Submits Marketing Authorization Application for Oritavancin
|
(Targanta Therapeutics)
|
09-Jun-2008 |
| ADA - DPP-IVs and GLP-1s steal the show
|
(Merck & Co)
|
09-Jun-2008 |
| Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
|
(Eli Lilly)
|
07-Jun-2008 |
| Monotherapy BYETTA® (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
|
(Eli Lilly)
|
07-Jun-2008 |
| Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
|
(Alkermes)
|
07-Jun-2008 |
| Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
|
(Amylin Pharmaceuticals)
|
07-Jun-2008 |
| Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
|
(Amylin Pharmaceuticals)
|
07-Jun-2008 |
| ASCO - ImClone falls as investors not wild about Erbitux biomarker
|
(ImClone Systems)
|
02-Jun-2008 |
| New Analyses of Pivotal Phase 3 Study of ERBITUX(R) Demonstrate Enhanced Efficacy in First-Line Metastatic Colorectal Cancer Patients with Wild-Type K-Ras Biomarker
|
(ImClone Systems)
|
01-Jun-2008 |
| Merck KGaA: Erbitux – Enhanced Efficacy Demonstrated in Patients KRAS Wild-Type Tumors in First-Line Metastatic Colorectal Cancer
|
(Merck KGaA)
|
01-Jun-2008 |
| ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
|
(Bristol-Myers Squibb)
|
31-May-2008 |
| ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
|
(ImClone Systems)
|
31-May-2008 |
| RTOG Study: Adding Cetuximab to Chemotherapy and Radiotherapy Leads to Improved Outcome for Lung Cancer Patients
|
(ImClone Systems)
|
31-May-2008 |
| Merck KGaA: Erbitux Significantly Prolongs Survival in First-Line Treatment of Non-Small Cell Lung Cancer
|
(Merck KGaA)
|
31-May-2008 |
| Merck Receives CHMP Positive Opinion for Marketing Authorization Erbitux Including First-Line Colorectal Cancer in the European Union
|
(Merck KGaA)
|
30-May-2008 |
| Lilly Submits Cymbalta® Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
|
(Eli Lilly)
|
29-May-2008 |
| Study Showed ALIMTA® (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer
|
(Eli Lilly)
|
28-May-2008 |
| BioMS Medical’s Relapsing-remitting Multiple Sclerosis Trial Receives Positive Review from Data Safety Monitoring Board
|
(BioMS Medical)
|
27-May-2008 |
| Phase I/II Studies of IMC-A12 in Pancreatic Cancer Open for Patient Enrollment
|
(ImClone Systems)
|
20-May-2008 |
| Adolor and GlaxoSmithKline Announce FDA Approval of Entereg(R) (alvimopan) for the Management of Postoperative Ileus (POI)
|
(Adolor)
|
20-May-2008 |
| ERBITUX(R) (cetuximab) Data Demonstrate Improvements in Response Rate and Progression-Free Survival in Wild Type K-Ras Metastatic Colorectal Cancer Patients in First-Line Setting
|
(ImClone Systems)
|
16-May-2008 |
| ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection)
|
(Eli Lilly)
|
15-May-2008 |
| Investors nervous ahead of ASCO Erbitux data
|
(ImClone Systems)
|
13-May-2008 |
| Phase II Study of IMC-A12 for Advanced Liver Cancer Opens for Patient Enrollment
|
(ImClone Systems)
|
13-May-2008 |
| Adolor Provides Regulatory Update on Entereg(R) (alvimopan)
|
(Adolor)
|
09-May-2008 |
| FDA Approves Strattera® for Maintenance of ADHD in Children and Adolescents
|
(Eli Lilly)
|
08-May-2008 |
| Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
|
(AstraZeneca)
|
04-May-2008 |
| Vertex Announces Positive Interim Results with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who Failed to Achieve SVR with Previous Pegylated Interferon & Ribavirin Treatment
|
(Vertex Pharmaceuticals)
|
24-Apr-2008 |
| ImClone Announces Agreement with FDA on Special Protocol Assessment for Phase III Study of IMC-1121B in Breast Cancer
|
(ImClone Systems)
|
22-Apr-2008 |
| Erbitux leaked lung cancer data attracts interest
|
(Merck KGaA)
|
21-Apr-2008 |
| Teva Announces Tentative Approval of Generic Evista® Tablets
|
(Teva Pharmaceutical Industries)
|
17-Apr-2008 |
| Anthera Presents Data on Varespladib at ATVB Meeting
|
(Anthera Pharmaceuticals)
|
17-Apr-2008 |
| DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
|
(Anthera Pharmaceuticals)
|
16-Apr-2008 |
| SGX Presents Preclinical MET Data at AACR
|
(SGX Pharmaceuticals)
|
15-Apr-2008 |
| BioMS Medical’s Phase III U.S. Multiple Sclerosis Trial Receives Positive Safety Review from Data Safety Monitoring Board
|
(BioMS Medical)
|
15-Apr-2008 |
| ALIMTA® (pemetrexed for injection) Receives European Approval for Histologically-Based Use in First-Line Treatment of Most Common Lung Cancer
|
(Eli Lilly)
|
11-Apr-2008 |
| Targanta Announces FDA Acceptance of Oritavancin New Drug Application
|
(Targanta Therapeutics)
|
09-Apr-2008 |
| Phase II Study of IMC-A12 for Advanced Head and Neck Cancer Commences Patient Enrollment
|
(ImClone Systems)
|
09-Apr-2008 |
| Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease
|
(Eli Lilly)
|
31-Mar-2008 |
| Phase II Results for CDP791 in Non-Small Cell Lung Cancer Support Further Clinical Development
|
(UCB)
|
31-Mar-2008 |
| New Data Showed ACTOS® (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients with Type 2 Diabetes
|
(Takeda)
|
31-Mar-2008 |
| Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
|
(Eli Lilly)
|
29-Mar-2008 |
| Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
|
(Daiichi Sankyo)
|
29-Mar-2008 |
| SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials
|
(SGX Pharmaceuticals)
|
27-Mar-2008 |
| New Studies Confirm the Benefits of Dapoxetine as a Treatment of Premature Ejaculation
|
(Johnson & Johnson)
|
27-Mar-2008 |
| MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
|
(AstraZeneca)
|
18-Mar-2008 |
| Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
|
(Genaera)
|
18-Mar-2008 |
| No Sign of ANDA Filing for Daptomycin
|
(Cubist Pharmaceuticals)
|
13-Mar-2008 |
| Vertex Pharmaceuticals and Tibotec Announce Start of Phase 3 'ADVANCE' Study with Telaprevir in Treatment-Naive, Genotype 1 HCV Patients
|
(Vertex Pharmaceuticals)
|
13-Mar-2008 |
| Akorn-Strides, LLC Announces FDA Approval for Tobramycin Injection USP, 80 mg/2mL and 1.2 grams/30mL
|
(Akorn)
|
12-Mar-2008 |
| MannKind - last gasp for inhaled insulin
|
(Alkermes)
|
10-Mar-2008 |
| Alkermes Receives Notice from Eli Lilly Terminating Inhaled Insulin Program
|
(Alkermes)
|
07-Mar-2008 |
| Lilly Announces Termination of AIR Insulin Program
|
(Eli Lilly)
|
07-Mar-2008 |
| Phase I/II Studies of IMC-A12 in Pediatric Cancer Patients Commence Enrollment
|
(ImClone Systems)
|
05-Mar-2008 |
| Sun Pharma Gets USFDA Tentative Approval for Generic Gemzar® Injection
|
(Sun Pharmaceutical Industries)
|
05-Mar-2008 |
| BioMS Medical’s Relapsing-remitting Multiple Sclerosis Trial Receives Positive Review from Data Safety Monitoring Board
|
(BioMS Medical)
|
03-Mar-2008 |
| NPIL Research & Development Limited Commences Phase I Trials on New Molecule for Metabolic Disorders in Europe
|
(Piramal Healthcare)
|
29-Feb-2008 |
| FORSTEO® Receives Positive Opinion from the European Committee for Medicinal Products for Human Use for the Treatment of Glucocorticoid-Induced Osteoporosis
|
(Eli Lilly)
|
22-Feb-2008 |
| FDA decision strengthens chance of prasugrel approval
|
(Eli Lilly)
|
22-Feb-2008 |
| Phase II Study of IMC-1121B for Advanced Liver Cancer Commences Patient Enrollment
|
(ImClone Systems)
|
22-Feb-2008 |
| Lilly Launches KwikPen™ for Humalog® and Humalog Mixtures
|
(Eli Lilly)
|
21-Feb-2008 |
| FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, Prasugrel
|
(Eli Lilly)
|
21-Feb-2008 |
| FDA grants priority review for Daiichi Sankyo, Lilly drug, prasugrel
|
(Daiichi Sankyo)
|
21-Feb-2008 |
| Daiichi Sankyo, Lilly Submit Marketing Authorization Application for Investigational Oral Antiplatelet Drug, Prasugrel, to European Medicines Agency
|
(Daiichi Sankyo)
|
20-Feb-2008 |
| NRDL Announces Second Drug Development Agreement With Eli Lilly and Company
|
(Piramal Healthcare)
|
15-Feb-2008 |
| FDA Extends Review of NDA for ENTEREG(R) (alvimopan)
|
(Adolor)
|
08-Feb-2008 |
| FDA Advisory Committee Supports Efficacy and Safety of Zyprexa® Long-Acting Injection (LAI) for Schizophrenia Treatment
|
(Eli Lilly)
|
06-Feb-2008 |
| MedImmune Submits Biologics License Application to FDA for Motavizumab
|
(AstraZeneca)
|
04-Feb-2008 |
| Adolor and GlaxoSmithKline Report Favorable FDA Advisory Committee Meeting for ENTEREG(R) (alvimopan) for the Management of Postoperative Ileus in Bowel Resection
|
(Adolor)
|
23-Jan-2008 |
| U.S. Federal Trade Commission Clears Global Licensing and Development Agreement Between BioMS Medical and Lilly
|
(BioMS Medical)
|
23-Jan-2008 |
